CEO Joaquin Duato announced Johnson & Johnson will not develop GLP-1 drugs for the obesity market. The company will instead focus on sectors where it maintains a competitive advantage.
This strategy diverges from competitors Eli Lilly and Novo Nordisk, who remain heavily invested in weight-loss treatments. J&J will prioritize its internal pipeline in oncology and neuroscience.
Duato set a target for J&J to become the world’s leading cancer drug manufacturer by 2030. The pivot leverages existing strengths following the spinoff of the company's consumer health business.